Reconstituting Neuromodulators In Clinical Practice
Abstract
Neuromodulators have been used in clinical practice for decades, for both therapeutic and cosmetic applications. They are neuromuscular blocking agents that inhibit acetylcholine (ACh) release. In dermatology, they are typically used for temporary improvement in the appearance of dynamic, and to an extent, static lines. Facial aging is a result of a host of both extrinsic and intrinsic factors, including ultraviolet radiation, gravity, atrophy and remodeling of adipose, osseous, and cartilaginous structures, and changes in the muscle activity of facial musculature. Neuromodulators can be used to treat muscle hyperactivity, unwanted muscle movement contributing to wrinkle formation, asymmetries, and can also be used to treat hyperhidrosis.
References
Hexsel D, Hexsel CL. Botulinum Toxins. In: Robinson JK, ed. Surgery of the Skin: Procedural Dermatology, 3e. London, New York, Oxford, Philadelphia, St Louis, Sydney, Toronto: Saunders Elsevier Inc. 2015;427-440.
BOTOX Cosmetic (onabotulinumtoxinA). Package insert. Allergan, inc. 2020.
Health Canada; 2020. ONA Product Monograph. Available from: https://pdf. hres.ca/dpd_pm/00057811.PDF
Health Canada; 2019. XEOMIN COSMETICTM Product Monograph. Available from https://pdf.hres.ca/dpd_ pm/00051826.PDF
Health Canada; 2020. ABO Product Monograph. Available from https://pdf. hres.ca/dpd_pm/00058388.PDF
Hexsel D, Mazzuco R, Dal’Forno T, et al.: Botulinum toxin for facial wrinkles: history and future. Expert Rev Dermatol. 2007;2:417-427.
Health Canada; 2021. BOTOX® Product Monograph. Available from: https://pdf. hres.ca/dpd_pm/00060199.PDF
Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-849.
Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004;51:223-233.
Monheit G, Carruthers A, Brandt F, et al. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007;33(Suppl. 1):51-59.
Hexsel D, Brum C, do Prado DZ, et al. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial. J Am Acad Dermatol. 2012;67(2):226-232.
Kerscher M, Roll S, Becker A: Comparison of the spread of three botulinum toxin type A preparations. Arch Dermatol Res. 2012;304:155-161.
Dressler D, Mander G, Fink K: Measuring the potency labelling of onabotulinumtoxin A (Botox®) and incobotulinumtoxinA (Xeomin® ) in an LD50 assay. J Neural Transm. 2012;119(1):13-15.
De Morais OO, Reis-Filho EM, Pereira LV, et al. Comparison of four botulinum neurotoxin type A preparations in the treatment of hyperdynamic forehead lines in men: a pilot study. J Drugs Dermatol. 2012;11(2):216-219.
Hexsel DM, Almeida AT, Rutowitsch M, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg. 2003;29:523-529.
Hexsel D, Castro IA, Zechmeister D, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin A reconstituted up to six consecutive weeks before application. Dermatol Surg. 2004;30:823.
Hexsel D, Rutowitsch M, Castro LC, et al. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection. Dermatol Surg. 2009;35:933-939.
